Novartis Institutes for BioMedical Research Unveils Redesigned Water Tower and Announces Educational Collaborations

Neighborhood Open House Celebrates New Research Headquarters



Nov 09, 2004, 00:00 ET from Novartis Institutes for BioMedical Research

    CAMBRIDGE, Mass., Nov. 9 /PRNewswire/ -- A new landmark on the Cambridge
 skyline was unveiled today as the Novartis Institutes for BioMedical Research
 (NIBR) revealed the new look for the water tower atop its world research
 headquarters.  Today's community open house celebrated the transformation of
 the site -- the former home of the New England Confectionery Company (NECCO)
 -- from a candy factory into a state-of-the-art drug discovery research
 laboratory.  The new water tower design maintains the colorful spirit of the
 old tower by incorporating the colors from the old NECCO tower in the bonded
 pairs of the new design, a DNA double helix that wraps around the tower.
 Today's event also included the announcement of two exciting educational
 collaborations sponsored by NIBR, the research division of Novartis, and
 featured remarks from Cambridge Mayor Michael Sullivan, Art Solomon, President
 of the DSF Group, and Mark Fishman, President of NIBR.
     (Photo:  http://www.newscom.com/cgi-bin/prnh/20041109/NETU025 )
 
     The work of a local artist
     In 1996, to celebrate its 150 year anniversary, NECCO painted the water
 tower on the roof of its factory to resemble its popular multi-colored wafer
 candy roll.
     As the building's new occupant, Novartis committed to maintaining the
 tower as a colorful landmark, but wanted to ensure that the tower's design
 reflected the new life of the building beneath it.  To do this, in February
 2004, the company sponsored a "competition of ideas," soliciting design ideas
 from the arts, design and school communities in Cambridge.  After receiving
 more than 500 designs from artists of all ages, in April of 2004, a jury of
 experts awarded cash prizes to multiple entrants in six categories.  In
 addition, each Cambridge Public School that submitted at least one design was
 awarded a $500 grant for art supplies and each student that submitted a design
 was given two passes to Boston's Museum of Science.
     The design of the newly unveiled tower was inspired by the work of
 Somerville resident Joseph Depasquale, a student at the Katherine Martin
 Widmer School of Painting.  Depasquale entered the design contest at the
 urging of Widmer, who had heard about the contest from a newspaper story.  "I
 researched Novartis after I read the contest rules," said Depasquale, "and I
 decided that the DNA helix was a natural fit."
 
     A commitment to education
     At today's community event, NIBR also announced two important new
 educational collaborations with area schools.  The first program, the Novartis
 
 Science Teachers Exchange, will be funded by NIBR and coordinated by Boston's
 Museum of Science.  The focus of this program is on improving biotechnology-
 related curriculum in Europe and the U.S. by facilitating an exchange of ideas
 and best practices between high school biology teachers in Cambridge/Boston
 and Basel, Switzerland -- where Novartis' corporate headquarters is located.
     Four teachers and a coordinator from each of the two cities will form a
 collaborative team to explore efforts and develop new ideas for introducing
 biotechnology into the high school curriculum.  "Educators in the U.S. and
 Europe have developed and implemented innovative lessons that engage students'
 interest while teaching the fundamentals of biology, but there has been very
 little international exchange of ideas.  We are excited that this program will
 be a key step in dissemination of biotechnology curriculum on both sides of
 the Atlantic," said Cary Sneider, Vice President for Educator Programs at the
 Museum of Science.
     The second collaboration is called the "Netpals" program, and pairs up
 NIBR scientists with 7th grade students from Cambridgeport Elementary School.
 During the school year, the scientists will serve as mentors on a variety of
 research and writing assignments and share information about their education
 and career paths.  The students will benefit from the one-on-one exchange with
 adults who love science.  "Netpals" programs are coordinated by Cambridge
 School Volunteers, Inc., in collaboration with individual schools.
     "In our neighboring schools today are the scientists of tomorrow," said
 Fishman.  "If we can, in any way, encourage them in this pursuit we are
 helping meet our commitment to the health care of the future."
 
     Novartis Institutes for BioMedical Research
     Novartis Institutes for BioMedical Research is Novartis' global research
 organization and is committed to discovering innovative medicines that cure
 disease and improve human health.  By conducting more relevant and predictable
 drug discovery that can yield new and better medicines for patients, Novartis
 Institutes for BioMedical Research is redefining drug discovery in the post-
 genomic era.  Over the past four years, Novartis Pharmaceuticals has had the
 greatest number of new molecular entities approved by the U.S. FDA.  With its
 broad focus on diseases for which there is need for better medical therapies
 and with 3,000 talented, dedicated research scientists worldwide, Novartis
 Institutes for BioMedical Research is well-positioned to ensure Novartis
 maintains its strong pipeline and highly successful track record in new drug
 discovery.  Novartis Institutes includes sites in Cambridge, Massachusetts
 (headquarters); Basel, Switzerland; Horsham & London, UK; East Hanover, NJ;
 Vienna, Austria; and Tsukuba, Japan.
 
      Novartis Institutes for BioMedical Research
      Contact: Jeff Lockwood
      phone: 617-871-7026
 
      Feinstein Kean Healthcare
      Contact: Manisha Pai
      phone: 617-761-6719
 
 

SOURCE Novartis Institutes for BioMedical Research
    CAMBRIDGE, Mass., Nov. 9 /PRNewswire/ -- A new landmark on the Cambridge
 skyline was unveiled today as the Novartis Institutes for BioMedical Research
 (NIBR) revealed the new look for the water tower atop its world research
 headquarters.  Today's community open house celebrated the transformation of
 the site -- the former home of the New England Confectionery Company (NECCO)
 -- from a candy factory into a state-of-the-art drug discovery research
 laboratory.  The new water tower design maintains the colorful spirit of the
 old tower by incorporating the colors from the old NECCO tower in the bonded
 pairs of the new design, a DNA double helix that wraps around the tower.
 Today's event also included the announcement of two exciting educational
 collaborations sponsored by NIBR, the research division of Novartis, and
 featured remarks from Cambridge Mayor Michael Sullivan, Art Solomon, President
 of the DSF Group, and Mark Fishman, President of NIBR.
     (Photo:  http://www.newscom.com/cgi-bin/prnh/20041109/NETU025 )
 
     The work of a local artist
     In 1996, to celebrate its 150 year anniversary, NECCO painted the water
 tower on the roof of its factory to resemble its popular multi-colored wafer
 candy roll.
     As the building's new occupant, Novartis committed to maintaining the
 tower as a colorful landmark, but wanted to ensure that the tower's design
 reflected the new life of the building beneath it.  To do this, in February
 2004, the company sponsored a "competition of ideas," soliciting design ideas
 from the arts, design and school communities in Cambridge.  After receiving
 more than 500 designs from artists of all ages, in April of 2004, a jury of
 experts awarded cash prizes to multiple entrants in six categories.  In
 addition, each Cambridge Public School that submitted at least one design was
 awarded a $500 grant for art supplies and each student that submitted a design
 was given two passes to Boston's Museum of Science.
     The design of the newly unveiled tower was inspired by the work of
 Somerville resident Joseph Depasquale, a student at the Katherine Martin
 Widmer School of Painting.  Depasquale entered the design contest at the
 urging of Widmer, who had heard about the contest from a newspaper story.  "I
 researched Novartis after I read the contest rules," said Depasquale, "and I
 decided that the DNA helix was a natural fit."
 
     A commitment to education
     At today's community event, NIBR also announced two important new
 educational collaborations with area schools.  The first program, the Novartis
 
 Science Teachers Exchange, will be funded by NIBR and coordinated by Boston's
 Museum of Science.  The focus of this program is on improving biotechnology-
 related curriculum in Europe and the U.S. by facilitating an exchange of ideas
 and best practices between high school biology teachers in Cambridge/Boston
 and Basel, Switzerland -- where Novartis' corporate headquarters is located.
     Four teachers and a coordinator from each of the two cities will form a
 collaborative team to explore efforts and develop new ideas for introducing
 biotechnology into the high school curriculum.  "Educators in the U.S. and
 Europe have developed and implemented innovative lessons that engage students'
 interest while teaching the fundamentals of biology, but there has been very
 little international exchange of ideas.  We are excited that this program will
 be a key step in dissemination of biotechnology curriculum on both sides of
 the Atlantic," said Cary Sneider, Vice President for Educator Programs at the
 Museum of Science.
     The second collaboration is called the "Netpals" program, and pairs up
 NIBR scientists with 7th grade students from Cambridgeport Elementary School.
 During the school year, the scientists will serve as mentors on a variety of
 research and writing assignments and share information about their education
 and career paths.  The students will benefit from the one-on-one exchange with
 adults who love science.  "Netpals" programs are coordinated by Cambridge
 School Volunteers, Inc., in collaboration with individual schools.
     "In our neighboring schools today are the scientists of tomorrow," said
 Fishman.  "If we can, in any way, encourage them in this pursuit we are
 helping meet our commitment to the health care of the future."
 
     Novartis Institutes for BioMedical Research
     Novartis Institutes for BioMedical Research is Novartis' global research
 organization and is committed to discovering innovative medicines that cure
 disease and improve human health.  By conducting more relevant and predictable
 drug discovery that can yield new and better medicines for patients, Novartis
 Institutes for BioMedical Research is redefining drug discovery in the post-
 genomic era.  Over the past four years, Novartis Pharmaceuticals has had the
 greatest number of new molecular entities approved by the U.S. FDA.  With its
 broad focus on diseases for which there is need for better medical therapies
 and with 3,000 talented, dedicated research scientists worldwide, Novartis
 Institutes for BioMedical Research is well-positioned to ensure Novartis
 maintains its strong pipeline and highly successful track record in new drug
 discovery.  Novartis Institutes includes sites in Cambridge, Massachusetts
 (headquarters); Basel, Switzerland; Horsham & London, UK; East Hanover, NJ;
 Vienna, Austria; and Tsukuba, Japan.
 
      Novartis Institutes for BioMedical Research
      Contact: Jeff Lockwood
      phone: 617-871-7026
 
      Feinstein Kean Healthcare
      Contact: Manisha Pai
      phone: 617-761-6719
 
 SOURCE  Novartis Institutes for BioMedical Research